PHOSPHORYLATED FATTY ACID SYNTHASE AND CANCER
The disclosed invention relates to the detection of phosphorylated fatty acid synthase as a diagnostic and a component in the identification and treatment of cancer. The disclosed methods permit early and accurate diagnosis of cancer to enable more effective therapy and to enhance patient survival and quality of life.
1 - 12 . (canceled)
13 . A method of identifying the presence of cancer in a subject, said method comprising:
detecting the presence of a fatty acid synthase (FAS) polypeptide comprising a phosphorylated threonine residue represented by position 1982 in SEQ ID NO:1 or by position 1984 in SEQ ID NO:2, or a fragment of said polypeptide comprising said phosphorylated threonine residue, in a biological sample from said subject.
14 . A method of monitoring cancer burden in a subject, said method comprising
measuring the level of a fatty acid synthase (FAS) polypeptide comprising a phosphorylated threonine residue represented by position 1982 in SEQ ID NO:1 or by position 1984 in SEQ ID NO:2, or a fragment of said polypeptide comprising said phosphorylated threonine residue, in a biological sample from said subject; and
repeating said measuring over time, wherein an increase or decrease in the level over time indicates an increase or decrease, respectively, in cancer burden.
15 . The method of claim 13 , wherein said FAS polypeptide comprising one or more phosphorylated amino acid residue has a relative molecular weight of about 270 kDa and a length of 2509 amino acid residues or less, or 2511 amino acid residues or less.
16 . The method of claim 13 , wherein said FAS polypeptide fragment has a length of at least 5 amino acid residues and comprises said phosphorylated threonine residue.
17 . The method of claim 13 , wherein said biological sample is selected from a blood sample, a serum sample, a plasma sample or a tumor cell containing sample.
18 . The method of claim 13 , wherein said cancer is breast cancer.
19 . The method of claim 14 , wherein said FAS polypeptide comprising one or more phosphorylated amino acid residue has a relative molecular weight of about 270 kDa and a length of 2509 amino acid residues or less, or 2511 amino acid residues or less.
20 . The method of claim 14 , wherein said FAS polypeptide fragment has a length of at least 5 amino acid residues and comprises said phosphorylated threonine residue.
21 . The method of claim 14 , wherein said biological sample is selected from a blood sample, a serum sample, a plasma sample or a tumor cell containing sample.
22 . The method of claim 14 , wherein said cancer is breast cancer.
23 . An antibody that binds an epitope comprising a phosphorylated threonine in a fatty acid synthase (FAS) polypeptide, or in a fragment of said polypeptide comprising said phosphorylated threonine residue,
wherein said phosphorylated threonine residue is represented by position 1982 in SEQ ID NO:1 or by position 1984 in SEQ ID NO:2.
24 . The antibody of claim 23 , wherein said FAS polypeptide has a relative molecular weight of about 270 kDa and a length of 2509 amino acid residues or less, or 2511 amino acid residues or less.
25 . The antibody of claim 23 , wherein said FAS polypeptide fragment has a length of at least 5 amino acid residues and comprises said phosphorylated threonine residue.
26 . The antibody of claim 23 , wherein said antibody binds the epitope in a blood sample, a serum sample, a plasma sample or a tumor cell containing sample.
27 . The antibody of claim 23 , which is a monoclonal antibody.
28 . The antibody of claim 23 , wherein said antibody binds the epitope in a blood sample, a serum sample, a plasma sample or a tumor cell containing sample.